Alongside the recommended control of classical risk factors such as AH and hyperglycemia with common pharmacological tools, in particular angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blocker (ARB), we explore the potential role of the new renin–angiotensin system (RAAS) blocker mediated by the novel nonsteroidal receptor antagonist finerenone and sodium–glucose cotransporter-2 (SGLT-2) inhibition on CKD management. This evidence concerns the gene ACE and Hyperglycemia.